Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.250
+0.010 (0.31%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Rocket Pharmaceuticals stock have an average target of 9.78, with a low estimate of 3.00 and a high estimate of 16. The average target predicts an increase of 200.92% from the current stock price of 3.25.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 14 | 14 | 14 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $10 | Buy | Maintains | $10 | +207.69% | Jun 11, 2026 |
| TD Cowen | TD Cowen | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 11, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $11 | Buy | Reiterates | $11 | +238.46% | May 10, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $10 | Buy | Maintains | $10 | +207.69% | May 8, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $12 | Buy | Reiterates | $12 | +269.23% | May 8, 2026 |
Financial Forecast
Revenue This Year
17.17M
Revenue Next Year
19.80M
from 17.17M
Increased by 15.32%
EPS This Year
-0.74
from -1.98
EPS Next Year
-1.16
from -0.74
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 180.9M | 130.0M | |
| Avg | 17.2M | 19.8M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 657.2% | 1,945.7% |
| Avg | 15.3% | 228.4% |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.16 | -0.12 | |
| Avg | -0.74 | -1.16 | |
| Low | -1.98 | -1.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.